Gilead's BIC/LEN Tablet Approved by FDA as New HIV Treatment

Gilead's New HIV Treatment: BIC/LEN Approved by the FDA

On August 27, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved a new HIV treatment, its Bictegravir 75 mg/Lenacapavir 50 mg tablet (BIC/LEN). This single-tablet regimen offers a crucial option for adults living with HIV who have achieved viral suppression through complex multi-tablet regimens, providing a simplified treatment path with just one daily dose.

BIC/LEN combines Bictegravir, a highly resilient integrase inhibitor with no cross-resistance to other antiretrovirals, and Lenacapavir, a first-in-class capsid inhibitor that acts through a novel mechanism. This combination represents a significant advancement in HIV treatment, particularly for patients who are unable to benefit from existing treatment regimens due to resistance or tolerability issues.

Dr. Chloe Orkin, the principal investigator of the ARTISTRY-1 trial and a professor at Queen Mary University of London, expressed, "BIC/LEN addresses the needs of people living with HIV by providing a new single-tablet regimen. The FDA approval marks an essential milestone in HIV therapy, especially for patients burdened by existing resistance and tolerability issues, offering a much-needed simplified dosing option."

The approval is based on the results of Phase III trials, ARTISTRY-1 and ARTISTRY-2, which assessed BIC/LEN in adult HIV patients who had achieved viral suppression, including those transitioned from complex multi-tablet regimens. In these studies, BIC/LEN maintained viral suppression just as effectively as control groups, and the safety profile was generally favorable with no major new safety concerns identified. Headache, nausea, and diarrhea were among the most reported side effects, each occurring in over 2% of participants in the ARTISTRY program. Detailed results of these trials were published in reputable journals, including The Lancet and Lancet HIV.

Gilead's CEO, Daniel O'Day, noted the significance of this approval, stating that BIC/LEN reflects the company’s commitment to innovation in the HIV sector. He emphasized that it offers new options for individuals living with HIV seeking to simplify their treatment regimen, supporting Gilead's goal of providing various treatment options for the management and prevention of HIV. O'Day also highlighted the company’s pipeline for further approvals in the coming years, including one pill daily, once-weekly, and long-acting formulations.

The ARTISTRY-1 trial included a unique participant demographic, with the median age being 60 years. Patients enrolled were previously on two to eleven antiretroviral medications daily, with approximately 40% taking multiple doses per day. Notably, 81% of participants had a history of antiretroviral drug resistance, highlighting the pressing need for treatment options like BIC/LEN. The trial also demonstrated improvements in fasting lipid parameters and greater treatment satisfaction among those switching to BIC/LEN from more complex regimens.

Starting BIC/LEN requires a two-day lead-in period where Lenacapavir is administered alongside BIC/LEN, followed by once-daily dosing thereafter. Currently, BIC/LEN is not approved for use outside the U.S.

While there remains no cure for HIV or AIDS, BIC/LEN stands as a promising therapeutic option for managing HIV in patients who have achieved viral suppression with complex treatment regimens. The specific indications and safety information for BIC/LEN in the U.S. include restrictions on its combination use with certain drugs and necessitate careful monitoring due to potential drug interactions and side effects.

Gilead has been a leader in the HIV therapeutic landscape for nearly four decades, pioneering several treatment advancements, including the first single-tablet regimen for HIV and pre-exposure prophylaxis (PrEP). Their commitment to continual scientific innovation focuses on addressing the evolving needs of HIV-positive individuals globally. Gilead also actively participates in charitable endeavors to enhance access to treatment and education, striving towards the ultimate goal of ending the HIV epidemic worldwide.

For BIC/LEN and its role in the fight against HIV, Gilead looks forward to fulfilling its promise to improve the lives of millions living with this chronic condition through innovative, effective treatments.